WO2010111634A3 - Renin inhibitors - Google Patents

Renin inhibitors Download PDF

Info

Publication number
WO2010111634A3
WO2010111634A3 PCT/US2010/028890 US2010028890W WO2010111634A3 WO 2010111634 A3 WO2010111634 A3 WO 2010111634A3 US 2010028890 W US2010028890 W US 2010028890W WO 2010111634 A3 WO2010111634 A3 WO 2010111634A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
renin inhibitors
relates
kits
intermediates
Prior art date
Application number
PCT/US2010/028890
Other languages
French (fr)
Other versions
WO2010111634A2 (en
Inventor
Jason W. Brown
Walter Keung
Zhe Li
John Tyhonas
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of WO2010111634A2 publication Critical patent/WO2010111634A2/en
Publication of WO2010111634A3 publication Critical patent/WO2010111634A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention relates to compounds having the formula: wherein the variables are as defined herein. The invention further relates to methods of making and using these compounds, intermediates which can be used to make the compounds, and pharmaceutical compositions, kits and articles of manufacture which contain the compounds.
PCT/US2010/028890 2009-03-26 2010-03-26 Renin inhibitors WO2010111634A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16377709P 2009-03-26 2009-03-26
US61/163,777 2009-03-26

Publications (2)

Publication Number Publication Date
WO2010111634A2 WO2010111634A2 (en) 2010-09-30
WO2010111634A3 true WO2010111634A3 (en) 2011-05-19

Family

ID=42320991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/028890 WO2010111634A2 (en) 2009-03-26 2010-03-26 Renin inhibitors

Country Status (1)

Country Link
WO (1) WO2010111634A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016079168A (en) * 2014-10-17 2016-05-16 塩野義製薬株式会社 9 membered condensed-ring derivative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064732A1 (en) * 2005-12-01 2007-06-07 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
WO2007070201A1 (en) * 2005-11-14 2007-06-21 Vitae Pharmaceuticals, Inc. Aspartic protease inhibitors
US20080009514A1 (en) * 2006-07-06 2008-01-10 Axel Stoit Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070201A1 (en) * 2005-11-14 2007-06-21 Vitae Pharmaceuticals, Inc. Aspartic protease inhibitors
WO2007064732A1 (en) * 2005-12-01 2007-06-07 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
US20080009514A1 (en) * 2006-07-06 2008-01-10 Axel Stoit Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JENNINGS L D ET AL: "Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB LNKD- DOI:10.1016/J.BMC.2004.07.031, vol. 12, no. 19, 1 October 2004 (2004-10-01), pages 5115 - 5131, XP004558890, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
WO2010111634A2 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
MY150596A (en) Hsp90 inhibitors
WO2010008847A3 (en) Pi3k/m tor inhibitors
MY150542A (en) Cmet inhibitors
PT2470546E (en) Hexahydrooxazinopteridine compounds for use as mtor inhibitors
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
WO2010111626A3 (en) Poly (adp-ribose) polymerase (parp) inhibitors
WO2009140624A3 (en) Glucokinase activators
UA110197C2 (en) To novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same
WO2010093191A3 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
WO2011033265A8 (en) Pharmaceutical compounds
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
WO2009139817A3 (en) Crystalline pharmaceutical and methods of preparation and use thereof
PL2250172T3 (en) Pyrrolopyrazine kinase inhibitors
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
BRPI0908926A2 (en) Polycarbonate-polyorganosiloxane and / or polyurethane-polyorganosiloxane compounds
MX2012004780A (en) Akt inhibitors.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2008121506A3 (en) Renin inhibitors
WO2010028122A8 (en) Process for making bivalirudin
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2009129401A8 (en) Kinase inhibitors
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010056585A3 (en) Heteroaryl diamide compounds useful as mmp-13 inhibitors
WO2009116081A3 (en) An improved process for the preparation of aprepitant
WO2008098143A3 (en) Antimicrobial compounds and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722831

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10722831

Country of ref document: EP

Kind code of ref document: A2